Strong Worldwide Procedure Growth
Total worldwide procedure growth was 20% with da Vinci and ION procedures increasing by 19% and 52% respectively.
Significant Revenue and Earnings Growth
Revenue grew 23% to $2.5 billion and earnings increased 30% year-over-year, reflecting strong operating discipline.
Successful Launch of da Vinci V
240 da Vinci V systems were placed, with the installed base now reaching 929 systems, driving higher utilization and efficiency.
Expansion into New Markets
First systems placed in Japan and Europe, with positive early feedback from these international markets.
Innovative Technological Advancements
FDA 510(k) clearance for software updates, enhancing surgeon awareness and intraoperative decision-making.
Positive Clinical Outcomes
Studies showed significant improvements in diagnostic yield and early-stage cancer diagnosis using ION and integrated mobile cone beam CT.